2021年最新SCI期刊影响因子查询系统
CANCER IMMUNOLOGY IMMUNOTHERAPY 期刊详细信息
基本信息
期刊名称 | CANCER IMMUNOLOGY IMMUNOTHERAPY CANCER IMMUNOLOGY IMMUNOTHERAPY |
---|---|
期刊ISSN | 0340-7004 |
期刊官方网站 | http://www.springer.com/medicine/internal/journal/262 |
是否OA | 否 |
出版商 | Springer Science and Business Media Deutschland GmbH |
出版周期 | Monthly |
始发年份 | |
年文章数 | 166 |
最新影响因子 | 6.63(2021) |
中科院SCI期刊分区
大类学科 | 小类学科 | Top | 综述 |
---|---|---|---|
医学2区 | IMMUNOLOGY 免疫学2区 | 否 | 否 |
ONCOLOGY 肿瘤学3区 |
CiteScore
CiteScore排名 | CiteScore | SJR | SNIP | ||
---|---|---|---|---|---|
学科 | 排名 | 百分位 | 4.40 | 2.085 | 0.969 |
Medicine Immunology and Allergy |
34 / 188 | 82% |
|||
Immunology and Microbiology Immunology |
40 / 198 | 80% |
|||
Biochemistry, Genetics and Molecular Biology Cancer Research |
51 / 191 | 73% |
|||
Medicine Oncology |
55 / 321 | 83% |
补充信息
自引率 | 3.00% |
---|---|
H-index | 97 |
SCI收录状况 |
Science Citation Index
Science Citation Index Expanded |
官方审稿时间 | |
网友分享审稿时间 | 数据统计中,敬请期待。 |
PubMed Central (PML) | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0340-7004%5BISSN%5D |
投稿指南
期刊投稿网址 | https://www.editorialmanager.com/ciim/default.aspx |
---|---|
收稿范围 | Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. In addition to publishing original research articles and reviews, CII also offers the following unique publication formats: · “Focussed Research Reviews,” published together with a conference meeting report, which provide individual speakers with the opportunity to expand on the ideas and concepts they presented at the conference. · “Symposia-in-Writing,” which are virtual workshops consisting of a series of complimentary papers centered on a specific issue and addressing controversial but strategic topics in the field, usually consisting of 4-8 papers and an accompanying commentary by the convener. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT), Sociedad Española de Immunologia-Grupo Español de ImmunoTerapia (SEI-GEIT), and Cancer Immunotherapy & Immunomonitoring (CITIM). |
收录体裁 | |
投稿指南 | |
投稿模板 | |
参考文献格式 | |
编辑信息 |